ELK4

Summary

ELK4 (ETS transcription factor ELK4, HGNC:3326) is a protein-coding gene on chromosome 1q32.1, encoding ETS domain-containing protein Elk-4 (P28324). Involved in both transcriptional activation and repression.

This gene is a member of the Ets family of transcription factors and of the ternary complex factor (TCF) subfamily. Proteins of the TCF subfamily form a ternary complex by binding to the the serum response factor and the serum reponse element in the promoter of the c-fos proto-oncogene. The protein encoded by this gene is phosphorylated by the kinases, MAPK1 and MAPK8. Several transcript variants have been described for this gene.

Source: NCBI Gene 2005 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 63 total
• Cancer driver (intOGen): activating (oncogene-like) across 1 cancer types
• MANE Select transcript: NM_001973

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3326
Approved symbol	ELK4
Name	ETS transcription factor ELK4
Location	1q32.1
Locus type	gene with protein product
Status	Approved
Aliases	SAP1
Ensembl gene	ENSG00000158711
Ensembl biotype	protein_coding
OMIM	600246
Entrez	2005

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000289703, ENST00000357992, ENST00000468523, ENST00000616704, ENST00000617725, ENST00000908985, ENST00000908986, ENST00000928041, ENST00000970515

RefSeq mRNA: 2 — MANE Select: NM_001973 NM_001973, NM_021795

CCDS: CCDS1456, CCDS1457

Canonical transcript exons

ENST00000357992 — 5 exons

Exon	Start	End
ENSE00001040443	205618957	205619073
ENSE00001372313	205619966	205620838
ENSE00001416662	205607943	205616644
ENSE00003720094	205623676	205623891
ENSE00003897670	205631632	205632011

Expression profiles

Bgee: expression breadth ubiquitous, 272 present calls, max score 97.40.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.6642 / max 142.0891, expressed in 1784 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
17004	6.6783	1695
17002	2.7563	1331
17001	2.4728	1276
17003	0.8972	550
17000	0.8597	487

Top tissues by expression

298 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tendon of biceps brachii	UBERON:0008188	97.40	gold quality
colonic epithelium	UBERON:0000397	95.41	gold quality
sperm	CL:0000019	95.11	gold quality
epithelium of nasopharynx	UBERON:0001951	94.32	gold quality
upper leg skin	UBERON:0004262	93.51	gold quality
skin of hip	UBERON:0001554	93.03	gold quality
biceps brachii	UBERON:0001507	92.93	gold quality
male germ cell	CL:0000015	92.86	gold quality
superficial temporal artery	UBERON:0001614	92.67	gold quality
parietal pleura	UBERON:0002400	92.58	gold quality
seminal vesicle	UBERON:0000998	92.46	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	92.45	gold quality
mammalian vulva	UBERON:0000997	92.40	gold quality
urethra	UBERON:0000057	92.27	gold quality
synovial joint	UBERON:0002217	92.26	gold quality
mammary duct	UBERON:0001765	92.14	gold quality
visceral pleura	UBERON:0002401	92.13	gold quality
oral cavity	UBERON:0000167	91.52	gold quality
tonsil	UBERON:0002372	91.38	gold quality
trabecular bone tissue	UBERON:0002483	91.38	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	91.11	gold quality
superior surface of tongue	UBERON:0007371	91.08	gold quality
pleura	UBERON:0000977	90.95	gold quality
endometrium	UBERON:0001295	90.63	gold quality
caput epididymis	UBERON:0004358	90.53	gold quality
cartilage tissue	UBERON:0002418	90.48	gold quality
tendon	UBERON:0000043	90.32	gold quality
vena cava	UBERON:0004087	90.32	gold quality
mucosa of paranasal sinus	UBERON:0005030	90.30	gold quality
tibia	UBERON:0000979	90.26	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-7316	yes	31.95
E-ANND-3	yes	6.89

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

7 targets.

Target	Regulation
CCT8
EGR1	Unknown
FOS	Activation
INSIG2	Activation
MCL1	Unknown
NR2C2	Unknown
TBXT

JASPAR motifs

Motif	Name	Family
MA0076.1	ELK4	Ets-related
MA0076.2	ELK4	Ets-related
MA0076.3	ELK4	Ets-related

JASPAR matrix evidence (PMIDs): PMID:8524663

Upstream regulators (CollecTRI, top): AR, FOXA1

miRNA regulators (miRDB)

51 targeting ELK4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-659-3P	99.85	70.69	1620
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-1255A	99.74	68.09	744
HSA-MIR-1255B-5P	99.74	68.16	741
HSA-MIR-4802-3P	99.72	70.13	1273
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-1208	99.70	68.28	1533
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-452-5P	99.65	69.63	1762
HSA-MIR-4676-3P	99.65	69.31	1733
HSA-MIR-892C-3P	99.65	69.38	1745
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-6751-5P	99.56	64.99	1145
HSA-MIR-7159-3P	99.51	70.17	1920
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-142-5P	99.48	70.92	2416

Literature-anchored findings (GeneRIF, showing 13)

• Crystal structure of a ternary SAP-1/SRF/c-fos SRE DNA complex (PMID:11846562)
• ELK4 is a direct androgen receptor target in prostate cancer cells. Androgens may thus contribute to the growth of prostate cancer via influencing ELK4 levels (PMID:18469865)
• SLC45A3-ELK4 may represent the first description of a recurrent RNA chimaeric transcript specific to prostate cancer that does not have a detectable DNA aberration (PMID:19136943)
• Data suggest that chimeric SLC45A3-ELK4 controls prostate cancer cell proliferation, and the chimera level correlates with prostate cancer disease progression. (PMID:22719019)
• ELK4 is overexpressed in melanoma and knocking down the ELK4 or CDK2 expression significantly attenuated the malignant phenotype of melanoma cells (PMID:26028036)
• CTCF has a role in regulating SLC45A3-ELK4 Chimeric RNA (PMID:26938874)
• Data suggest that SIRT7 undergoes Lys-63 polyubiquitination, later removed by USP7 to repress enzymatic activity of SIRT7; USP7 and SIRT7 regulate gluconeogenesis via expression of glucose-6-phosphatase catalytic subunit (G6PC); SIRT7 targets G6PC promoter through ELK4. (SIRT7 = sirtuin 7; USP7 = ubiquitin specific peptidase 7; G6PC = glucose-6-phosphatase catalytic subunit; ELK4 = transcription factor ELK4) (PMID:28655758)
• TRA2A-induced upregulation of LINC00662 regulates blood-brain barrier permeability by affecting ELK4 mRNA stability in Alzheimer’s microenvironment. (PMID:32372707)
• ELK4 promotes the development of gastric cancer by inducing M2 polarization of macrophages through regulation of the KDM5A-PJA2-KSR1 axis. (PMID:34372882)
• ELK4-mediated lncRNA SNHG22 promotes gastric cancer progression through interacting with EZH2 and regulating miR-200c-3p/Notch1 axis. (PMID:34663788)
• ELK4 Promotes Cell Cycle Progression and Stem Cell-like Characteristics in HPV-associated Cervical Cancer by Regulating the FBXO22/PTEN Axis. (PMID:37519006)
• IGF1R-phosphorylated PYCR1 facilitates ELK4 transcriptional activity and sustains tumor growth under hypoxia. (PMID:37777542)
• ELK4 targets CHMP6 to inhibit ferroptosis and enhance malignant properties of skin cutaneous melanoma cells. (PMID:39305302)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	elk4	ENSDARG00000077092
mus_musculus	Elk4	ENSMUSG00000026436
rattus_norvegicus	Elk4	ENSRNOG00000077523

Paralogs (28): ETV1 (ENSG00000006468), ETV7 (ENSG00000010030), SPI1 (ENSG00000066336), ELF4 (ENSG00000102034), ETV2 (ENSG00000105672), ERF (ENSG00000105722), ELF2 (ENSG00000109381), ELK3 (ENSG00000111145), ETV3 (ENSG00000117036), ELF1 (ENSG00000120690), SPDEF (ENSG00000124664), ELK1 (ENSG00000126767), ETS1 (ENSG00000134954), EHF (ENSG00000135373), ELF5 (ENSG00000135374), ETV6 (ENSG00000139083), FLI1 (ENSG00000151702), GABPA (ENSG00000154727), ERG (ENSG00000157554), ETS2 (ENSG00000157557), ELF3 (ENSG00000163435), FEV (ENSG00000163497), SPIC (ENSG00000166211), ETV4 (ENSG00000175832), ETV5 (ENSG00000244405), ETV3L (ENSG00000253831), ERFL (ENSG00000268041), SPIB (ENSG00000269404)

Protein

Protein identifiers

ETS domain-containing protein Elk-4 — P28324 (reviewed: P28324)

Alternative names: Serum response factor accessory protein 1

All UniProt accessions (2): A0A087X2F7, P28324

UniProt curated annotations — full annotation on UniProt →

Function. Involved in both transcriptional activation and repression. Interaction with SIRT7 leads to recruitment and stabilization of SIRT7 at promoters, followed by deacetylation of histone H3 at ‘Lys-18’ (H3K18Ac) and subsequent transcription repression. Forms a ternary complex with the serum response factor (SRF). Requires DNA-bound SRF for ternary complex formation and makes extensive DNA contacts to the 5’side of SRF, but does not bind DNA autonomously.

Subunit / interactions. Interacts with SIRT7.

Subcellular location. Nucleus.

Similarity. Belongs to the ETS family.

Isoforms (2)

UniProt ID	Names	Canonical?
P28324-1	1, SAP-1A	yes
P28324-2	2, SAP-1B

RefSeq proteins (2): NP_001964, NP_068567 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000418	Ets_dom	Domain
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR046328	ETS_fam	Family

Pfam: PF00178

UniProt features (28 total): helix 7, strand 6, region of interest 4, compositionally biased region 3, turn 2, chain 1, DNA-binding region 1, cross-link 1, splice variant 1, sequence conflict 1, modified residue 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
1BC8	X-RAY DIFFRACTION	1.93
1BC7	X-RAY DIFFRACTION	2.01
1HBX	X-RAY DIFFRACTION	3.15
1K6O	X-RAY DIFFRACTION	3.19

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P28324-F1	60.43	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 167, 180

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 309 (showing top): KEGG_MAPK_SIGNALING_PATHWAY, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, TURJANSKI_MAPK7_TARGETS, PAX8_B, IRF7_01, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM6, DER_IFN_BETA_RESPONSE_UP, RYTTCCTG_ETS2_B, KIM_GASTRIC_CANCER_CHEMOSENSITIVITY, TURJANSKI_MAPK14_TARGETS, IK2_01, WANG_RESPONSE_TO_FORSKOLIN_UP, NRF2_01, HAND1E47_01, DER_IFN_GAMMA_RESPONSE_UP

GO Biological Process (6): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), cell differentiation (GO:0030154), positive regulation of transcription by RNA polymerase II (GO:0045944), regulation of DNA-templated transcription (GO:0006355), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (9): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA binding (GO:0003677), chromatin binding (GO:0003682), DNA-binding transcription factor activity (GO:0003700), sequence-specific double-stranded DNA binding (GO:1990837), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of transcription by RNA polymerase II	3
transcription by RNA polymerase II	3
regulation of DNA-templated transcription	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
cellular anatomical structure	3
DNA-templated transcription	2
binding	2
negative regulation of DNA-templated transcription	1
cellular developmental process	1
positive regulation of DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
negative regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
nucleic acid binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
DNA binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

20 interactions, top by confidence:

A	B	Type	Score
SIRT7	ELK4	psi-mi:“MI:0915”(physical association)	0.520
SRF	ELK4	psi-mi:“MI:0407”(direct interaction)	0.410
	ELK4	psi-mi:“MI:0915”(physical association)	0.370
CCL2	ELK4	psi-mi:“MI:0915”(physical association)	0.370
CCL3	ELK4	psi-mi:“MI:0915”(physical association)	0.370
IL18	ELK4	psi-mi:“MI:0915”(physical association)	0.370
IL23A	ELK4	psi-mi:“MI:0915”(physical association)	0.370
IL36A	ELK4	psi-mi:“MI:0915”(physical association)	0.370
PPBP	ELK4	psi-mi:“MI:0915”(physical association)	0.370
TNFSF4	ELK4	psi-mi:“MI:0915”(physical association)	0.370
ELK4	MYO1C	psi-mi:“MI:0914”(association)	0.350
ELK4	PRPSAP2	psi-mi:“MI:0914”(association)	0.350
ELK4	HNRNPUL1	psi-mi:“MI:0914”(association)	0.350
CUL4A	DDX39A	psi-mi:“MI:0914”(association)	0.350
ELK4	GRPEL1	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (96): ELK4 (Synthetic Growth Defect), ELK4 (Synthetic Growth Defect), ELK4 (Biochemical Activity), ELK4 (Affinity Capture-MS), ELK4 (Affinity Capture-RNA), SIRT7 (Co-localization), ELK4 (Affinity Capture-RNA), ELK4 (Reconstituted Complex), ELK4 (Affinity Capture-Western), ELK4 (Affinity Capture-Western), DOK4 (Affinity Capture-Western), ELK4 (Reconstituted Complex), ELK4 (Co-localization), ELK4 (Affinity Capture-MS), IVNS1ABP (Affinity Capture-MS)

ESM2 similar proteins: A0A1L8H0H2, A0JN51, A4QNP0, F8VPJ6, O13186, O46567, O57415, O70477, O94842, P09775, P15257, P22361, P28324, P32519, P36197, P37275, P50534, P55347, P59759, P79686, Q05041, Q07243, Q0P5K4, Q14872, Q15723, Q2HJ84, Q2KHR2, Q3UH06, Q5R6A9, Q5W1J6, Q60542, Q60775, Q61321, Q62947, Q64318, Q6DJL0, Q6IRR0, Q6XLJ0, Q86T24, Q8AYC1

Diamond homologs: A0A1W2PQ73, A0JN51, A1A4L6, A1YF15, A1YG61, A1YG91, A2D4Z7, A2T737, A2T762, A3FEM2, A4GTP4, A8WFJ9, O00321, O01519, O70132, O70273, O95238, P01105, P10157, P11308, P11536, P13474, P14921, P15036, P15037, P15062, P18755, P18756, P19102, P19419, P20105, P26323, P27577, P28322, P28324, P29773, P29774, P29775, P29776, P32519

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
ELK4	“up-regulates quantity by expression”	INSIG2	“transcriptional regulation”
CDK2	“up-regulates activity”	ELK4	phosphorylation
PCSK7	up-regulates	ELK4	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 15 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
cellular response to lipopolysaccharide	5	32.7×	4e-05
inflammatory response	7	17.6×	1e-05

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 1 cancer types — HNSC.

Clinical variants and AI predictions

ClinVar

63 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	53
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1612 predictions. Top by Δscore:

Variant	Effect	Δscore
1:205616476:A:AC	donor_gain	1.0000
1:205616477:C:CC	donor_gain	1.0000
1:205616645:C:CC	acceptor_gain	1.0000
1:205600404:A:AG	acceptor_gain	0.9900
1:205600405:G:GA	acceptor_gain	0.9900
1:205600405:GTT:G	acceptor_gain	0.9900
1:205616477:CTT:C	donor_gain	0.9900
1:205616479:T:TA	donor_gain	0.9900
1:205616640:GGAAA:G	acceptor_gain	0.9900
1:205616641:GAAA:G	acceptor_gain	0.9900
1:205618953:TTA:T	donor_loss	0.9900
1:205618954:TA:T	donor_loss	0.9900
1:205618956:C:T	donor_loss	0.9900
1:205619070:GTGTC:G	acceptor_loss	0.9900
1:205619071:TGT:T	acceptor_gain	0.9900
1:205619071:TGTCT:T	acceptor_loss	0.9900
1:205619072:GTC:G	acceptor_loss	0.9900
1:205619073:TCTG:T	acceptor_loss	0.9900
1:205619074:C:CC	acceptor_gain	0.9900
1:205619074:CT:C	acceptor_loss	0.9900
1:205619075:T:C	acceptor_loss	0.9900
1:205620108:A:AC	donor_gain	0.9900
1:205620109:C:CC	donor_gain	0.9900
1:205631533:T:TA	donor_gain	0.9900
1:205631626:GCTCA:G	donor_loss	0.9900
1:205631627:CTCAC:C	donor_loss	0.9900
1:205631628:TCAC:T	donor_loss	0.9900
1:205631629:C:CC	donor_loss	0.9900
1:205631630:A:AC	donor_gain	0.9900
1:205631630:A:C	donor_loss	0.9900

AlphaMissense

2812 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:205620795:A:G	F84S	1.000
1:205623748:C:A	W45C	1.000
1:205623748:C:G	W45C	1.000
1:205623750:A:G	W45R	1.000
1:205623750:A:T	W45R	1.000
1:205623785:A:G	F33S	1.000
1:205623853:G:C	F10L	1.000
1:205623853:G:T	F10L	1.000
1:205623854:A:G	F10S	1.000
1:205623855:A:G	F10L	1.000
1:205620794:A:C	F84L	0.999
1:205620794:A:T	F84L	0.999
1:205620795:A:C	F84C	0.999
1:205620796:A:G	F84L	0.999
1:205620802:A:G	Y82H	0.999
1:205620806:A:C	F80L	0.999
1:205620806:A:T	F80L	0.999
1:205620808:A:G	F80L	0.999
1:205620825:T:A	K74I	0.999
1:205620831:A:T	I72N	0.999
1:205623692:C:A	R64I	0.999
1:205623692:C:G	R64T	0.999
1:205623695:A:G	L63P	0.999
1:205623695:A:T	L63H	0.999
1:205623701:C:G	R61P	0.999
1:205623702:G:C	R61G	0.999
1:205623707:A:G	L59P	0.999
1:205623717:A:G	Y56H	0.999
1:205623722:A:G	M54T	0.999
1:205623746:C:A	G46V	0.999

dbSNP variants (sampled 300 via entrez): RS1000054891 (1:205615132 C>A,T), RS1000120494 (1:205607626 C>A,T), RS1000123412 (1:205610550 C>T), RS1000186153 (1:205618334 ATT>A,AT,ATTT,ATTTT), RS1000302911 (1:205632778 T>C), RS1000355730 (1:205633024 T>C), RS1000594420 (1:205631791 G>A,C), RS1000647897 (1:205632858 T>G), RS1000717322 (1:205631070 A>T), RS1000828065 (1:205628179 C>T), RS1000998473 (1:205626503 G>C), RS1001109709 (1:205626747 G>A), RS1001175949 (1:205609377 G>T), RS1001322224 (1:205621285 C>G,T), RS1001536362 (1:205621887 CCA>C)

Disease associations

OMIM: gene MIM:600246 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

56 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	6
Cadmium Chloride	decreases expression, increases abundance, increases expression	3
Air Pollutants	increases abundance, increases expression, decreases expression	2
Cisplatin	decreases expression	2
Nickel	increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Smoke	increases abundance, decreases expression	2
aristolochic acid I	decreases expression	1
chloroacetaldehyde	increases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, decreases methylation	1
geraniol	increases expression	1
trichostatin A	decreases expression	1
2-butenal	decreases expression	1
sodium arsenite	affects splicing, increases abundance	1
ferrous chloride	increases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, decreases expression	1
asparanin A	decreases expression	1
Rosiglitazone	increases expression	1
Sunitinib	increases expression	1
Arsenic Trioxide	decreases methylation	1
Fulvestrant	affects cotreatment, decreases methylation	1
Cidofovir	decreases expression	1
Glyphosate	decreases expression	1
Arsenic	affects splicing, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Cadmium	decreases expression, increases abundance	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D8KS	Ubigene HCT 116 ELK4 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.